In November 2014 we signed an agreement with LONZA LTD for the manufacturing of our Adva-27a drug. Founded in 1897 in the Swiss Alps, LONZA is the world’s leading and most-trusted manufacturer of pharmaceutical products. LONZA has more than 40 major manufacturing facilities worldwide and is currently manufacturing 2 kilograms of our Adva-27a for clinical trials.
In June 2011, Sunshine Biopharma entered into a Clinical Trials Agreement with McGill University’s Jewish General Hospital to conduct certain research and development activities and advance Sunshine Biopharma’s lead compound, Adva-27a, through the various stages of preclinical studies and Phase I clinical trials on pancreatic cancer and multidrug resistant breast cancer patients.
In January 2011, Sunshine Biopharma entered into a collaboration agreement with State University of New York at Binghamton (Binghamton University) to conduct certain research and development activities aimed at advancing Sunshine Biopharma’s lead compound, Adva-27a, through various stages of preclinical development.
Sunshine Biopharma is planning to expand its product line through acquisitions and/or in-licensing as well as in-house research and development. Please submit your non-confidential project information to Camille Sebaaly at email@example.com for review and we will do our best to reply within two to four weeks.
© 2015 Sunshine Biopharma Inc., All Rights Reserved.